Company logo

ARVN - Arvinas, Inc.

NASDAQ -> Healthcare -> Biotechnology
New Haven, United States
Type: Equity

ARVN price evolution
ARVN
(in millions $) 30 Oct 2024 30 Jun 2024 31 Mar 2024 31 Dec 2023
Current assets
Cash $160.3 $93.5 $317.2
Short term investments $1073.9 $1081.3 $949.3
Net receivables $14.8 $10 $7.1 $7.2
Inventory
Total current assets $1149.5 $1256.7 $1190.3 $1280.2
Long term investments
Property, plant & equipment $7.8 $11.3 $12.4 $14
Goodwill & intangible assets
Total noncurrent assets $22.9 $22.3 $24.4
Total investments $1073.9 $1081.3 $949.3
Total assets $1167.1 $1279.6 $1212.6 $1304.6
Current liabilities
Accounts payable $93.6 $78.1 $76.4 $92.2
Deferred revenue $599.2 $523.9 $549.2
Short long term debt $1.2 $1.5 $1.9
Total current liabilities $275.9 $347.2 $240.8 $257.1
Long term debt $0.6 $0.9 $1.1 $1.3
Total noncurrent liabilities $332.2 $362.1 $387.5
Total debt $2.1 $2.6 $3.2
Total liabilities $581.1 $679.4 $602.9 $644.6
Shareholders' equity
Retained earnings -$1486.5 -$1437.3 -$1402.1 -$1332.7
Other shareholder equity $4.1 -$3.8 -$4.4 -$3.1
Total shareholder equity $600.2 $609.7 $660
(in millions $) 31 Dec 2023 31 Jan 2023 31 Dec 2021 31 Dec 2020
Current assets
Cash $317.2 $86.8 $112.8 $588.37
Short term investments $949.3 $1124 $1394.3 $100.16
Net receivables $7.2 $8 $25.7 $8.44
Inventory
Total current assets $1280.2 $1240.2 $1552.5 $703.09
Long term investments
Property, plant & equipment $14 $17.8 $16.6 $14.25
Goodwill & intangible assets
Total noncurrent assets $24.4 $28.6 $29.1 $14.28
Total investments $949.3 $1124 $1394.3 $100.16
Total assets $1304.6 $1268.8 $1581.6 $717.37
Current liabilities
Accounts payable $92.2 $5.7 $31.3 $7.12
Deferred revenue $549.2 $623.7 $740.5 $45.09
Short long term debt $1.9 $1.8 $1.1 $0.95
Total current liabilities $257.1 $295.1 $261.7 $49.09
Long term debt $1.3 $1 $3.9 $3.09
Total noncurrent liabilities $387.5 $408.8 $538.2 $26.03
Total debt $3.2 $5.5 $5 $4.04
Total liabilities $644.6 $703.9 $799.9 $75.11
Shareholders' equity
Retained earnings -$1332.7 -$965.4 -$682.9 -$491.89
Other shareholder equity -$3.1 -$19.2 -$4.6 $0.56
Total shareholder equity $660 $564.9 $781.7 $642.26
(in millions $) 30 Oct 2024 30 Jun 2024 31 Mar 2024 31 Dec 2023
Revenue
Total revenue $102.4 $76.5 $25.3 -$43.1
Cost of revenue
Gross Profit $76.5 $25.3 -$43.1
Operating activities
Research & development $93.7 $84.3 $95.2
Selling, general & administrative $31.3 $24.3 $27
Total operating expenses $162.7 $125 $108.6 $122.2
Operating income -$48.5 -$83.3 -$165.3
Income from continuing operations
EBIT -$35 -$69.3 -$153.2
Income tax expense $0.6 $0.2 $0.1 $1.6
Interest expense $14.3
Net income
Net income -$49.2 -$35.2 -$69.4 -$154.8
Income (for common shares) -$35.2 -$69.4 -$154.8
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 31 Dec 2020
Revenue
Total revenue $78.5 $131.4 $46.7 $21.8
Cost of revenue
Gross Profit $78.5 $131.4 $46.7 $21.8
Operating activities
Research & development $379.7 $315 $180.4 $108.36
Selling, general & administrative $100.3 $79.6 $61.6 $38.3
Total operating expenses $480 $394.6 $242 $146.66
Operating income -$401.5 -$263.2 -$195.3 -$124.86
Income from continuing operations
EBIT -$366.4 -$261.6 -$190.9 -$119.27
Income tax expense $0.9 $20.9
Interest expense $0.1 $0.07
Net income
Net income -$367.3 -$282.5 -$191 -$119.33
Income (for common shares) -$367.3 -$282.5 -$191 -$119.33
(in millions $) 30 Oct 2024 30 Jun 2024 31 Mar 2024 31 Dec 2023
Net income -$35.2 -$69.4 -$154.8
Operating activities
Depreciation $1.7 $1.7 $1.7
Business acquisitions & disposals
Stock-based compensation $21.6 $18.6 $16.7
Total cash flows from operations $50.3 -$97.5 -$83.1
Investing activities
Capital expenditures -$0.6 -$0.1 -$0.1
Investments $13.7 -$127.7 -$53.6
Total cash flows from investing -$64.2 $13.1 -$127.8 -$53.7
Financing activities
Dividends paid
Sale and purchase of stock $3.5 $1.8 $334.8
Net borrowings -$0.1 -$0.2
Total cash flows from financing $7.4 $3.4 $1.6 $334.8
Effect of exchange rate
Change in cash and equivalents -$232 $66.8 -$223.7 $198
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 31 Dec 2020
Net income -$367.3 -$282.5 -$191 -$119.33
Operating activities
Depreciation $6.7 $8.2 $6 $4.02
Business acquisitions & disposals
Stock-based compensation $71.6 $75.5 $57.1 $30.23
Total cash flows from operations -$347.8 -$273.5 $559.4 -$89.76
Investing activities
Capital expenditures -$2.9 -$6.8 -$4.7 -$6.45
Investments $206.4 $249.6 -$1308.9 $170.7
Total cash flows from investing $203.5 $242.8 -$1313.6 $164.25
Financing activities
Dividends paid
Sale and purchase of stock $374.7 $4.7 $278.6 $504.67
Net borrowings
Total cash flows from financing $374.7 $4.7 $278.6 $504.67
Effect of exchange rate
Change in cash and equivalents $230.4 -$26 -$475.6 $579.16
Fundamentals
Market cap $1.73B
Enterprise value N/A
Shares outstanding 68.70M
Revenue $161.10M
EBITDA N/A
EBIT N/A
Net Income -$308.60M
Revenue Q/Q 195.95%
Revenue Y/Y -3.65%
P/E ratio -5.59
EV/Sales N/A
EV/EBITDA N/A
EV/EBIT N/A
P/S ratio 10.71
P/B ratio N/A
Book/Share N/A
Cash/Share N/A
EPS -$4.49
ROA -24.87%
ROE N/A
Debt/Equity 0.98
Net debt/EBITDA N/A
Current ratio 4.17
Quick ratio N/A